Compare Harley-Davidson Inc (HOG) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Harley-Davidson Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Harley-Davidson Inc trades at $27.04 (market cap $2.78B), while State Street SPDR S&P Biotech ETF trades at $153.22 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 3.6× Harley-Davidson Inc's market cap, and Harley-Davidson Inc pays a 2.8% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Harley-Davidson Inc for 91 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| HOG | XBI | |
|---|---|---|
Market Cap | $2.78B | $10.11B |
Volume | 2,966,389 | 12,903,266 |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $28.46 | $169.55 |
52-Week Low | $17.19 | $104.99 |
Typical Hold Time | 91 Days | 37 Days |
Enterprise Value | $3.20B | — |
Dividend Yield | 2.8% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Harley-Davidson (HOG) trades at $26.95, up 0.04% on the day, with a bullish technical signal and mixed earnings history. The company reported Q2 2026 EPS of $0.75, beating expectations, but revenue has declined from $5.8B in 2022 to $4.5B in 2025. Valuation ratios appear attractive with a P/E of 14.86 and P/B of 0.9, while analyst consensus is a hold with a $28.50 price target. Recent news includes a data breach investigation and a new product collaboration.
The outlook for HOG is cautious due to declining revenue and profit margins, offset by reasonable valuations and positive technical momentum. Key risks include tariff exposure, competitive pressures, and ongoing data security issues. Upside potential exists if the 'Back to the Bricks' strategy reverses sales trends, but investors should weigh fundamental weaknesses against technical strength.
XBI trades at $150.23, down 0.44% on the day, with a bearish technical signal driven by moving averages and oscillators. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts. Recent news highlights sector optimism from cancer vaccine breakthroughs and improved capital access, though the ETF carries higher volatility than broader healthcare funds.
The outlook is mixed: strong sector tailwinds from innovation and consolidation support growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst sentiment is neutral with 100% hold ratings, suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Harley-Davidson Inc
Harley-Davidson is a global leading manufacturer of heavyweight motorcycles, merchandise, parts, and accessories. It sells custom, cruiser, and touring motorcycles and offers a complete line of Harley-Davidson motorcycle parts, accessories, riding gear, and apparel, as well as merchandise. Harley-Davidson Financial Services provides wholesale financing to dealers and retail financing and insurance brokerage services to customers. Harley has historically captured about half of all heavyweight domestic retail motorcycle registrations, a metric it had ceded in 2020 as it repositioned the business, but a level it is working back toward. In recent years the firm has expanded into the adventure touring market with its Pan America model and into electric with the LiveWire brand.
Read more on HOG →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
